RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC

Stopped Decision was made due to a strategic re-evaluation of pipelines; no patients were enrolled.

Conditions

• Cutaneous Squamous Cell Carcinoma
• Head and Neck Squamous Cell Carcinoma

Interventions

• COMBINATION_PRODUCT: RM-1995
• BIOLOGICAL: Pembrolizumab

Sponsor

Rakuten Medical, Inc.